NCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Completed
Clinical Trials
13 trialsNCT03542175 2025-12-08
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03552471 2025-02-13
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03958045 2024-10-22
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
Phase 2 Completed
NCT03413995 2024-10-16
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03911453 2024-10-03
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
University of Arizona
Phase EARLY_PHASE1 Completed
NCT01074970 2024-09-19
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
Phase 2 Completed
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed
NCT02505048 2021-06-08
RUBY
UNICANCER
Phase 2 Completed
NCT00664781 2016-05-24
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Cancer Research UK
Phase 2 Completed